SeouLin Bioscience서린바이오
038070 · KOSDAQ · ₩038070 · 서린바이오
₩3,670▲ ₩45 (1.24%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 21.4% | 22.5% | 25.2% | 22.2% | 23.1% | 26.0% |
| Operating margin | 0.6% | 0.9% | 1.3% | 2.8% | 8.4% | 9.0% |
| Net margin | 1.1% | 0.9% | 3.9% | −0.1% | 9.3% | 19.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +7.9% | +2.2% | −15.8% | −12.5% | +26.9% | — |
| Operating income growth | −27.1% | −27.4% | −61.8% | −70.9% | +18.2% | — |
| Net income growth | +25.2% | −74.9% | +2,579.0% | −101.2% | −38.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 1.1% | 0.9% | 3.5% | −0.1% | 12.0% | 20.8% |
| Return on assets | 0.8% | 0.5% | 2.9% | −1.9% | 7.4% | 11.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 34.6% | 38.1% | 16.9% | 33.9% | 53.0% | 78.5% |
| Net debt to equity | 4.2% | 1.1% | −6.3% | −9.8% | 9.8% | 0.9% |
| Current ratio | 273.3% | 227.5% | 438.9% | 260.3% | 186.9% | 406.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: SeouLin Bioscience / 서린바이오 / 038070 / KRX:038070
Source: KRX statistical information